IS4706A - pharmaceutical compositions - Google Patents

pharmaceutical compositions

Info

Publication number: IS4706A
Authority: IS; Iceland
Prior art keywords: pharmaceutical compositions; pharmaceutical; compositions
Prior art date: 1995-11-21

Application number

IS4706A

Other languages

Icelandic (is)

Inventor

James Macrae Ross

Sarah Smith Janet

Original Assignee

Pfizer Research And Development Company, N.V/S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-21

Filing date

1998-03-31

Publication date

1998-03-31

1998-03-31 Application filed by Pfizer Research And Development Company, N.V/S.A. filed Critical Pfizer Research And Development Company, N.V/S.A.

1998-03-31 Publication of IS4706A publication Critical patent/IS4706A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS4706A 1995-11-21 1998-03-31 pharmaceutical compositions IS4706A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9523752.5A GB9523752D0 (en)	1995-11-21	1995-11-21	Pharmaceutical formulations
PCT/EP1996/005020 WO1997018814A1 (en)	1995-11-21	1996-11-11	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
IS4706A true IS4706A (en)	1998-03-31

Family

ID=10784188

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS4706A IS4706A (en)	1995-11-21	1998-03-31	pharmaceutical compositions

Country Status (29)

Country	Link
EP (1)	EP0862437A1 (en)
JP (1)	JPH10513481A (en)
KR (1)	KR19990071505A (en)
CN (1)	CN1215993A (en)
AP (1)	AP718A (en)
AR (1)	AR004335A1 (en)
AU (1)	AU709560B2 (en)
BG (1)	BG102438A (en)
BR (1)	BR9611626A (en)
CA (1)	CA2232715A1 (en)
CO (1)	CO4480020A1 (en)
CZ (1)	CZ155498A3 (en)
GB (1)	GB9523752D0 (en)
HR (1)	HRP960554A2 (en)
HU (1)	HUP9903734A3 (en)
IS (1)	IS4706A (en)
MA (1)	MA26410A1 (en)
MX (1)	MX9804008A (en)
NO (1)	NO982302L (en)
NZ (1)	NZ322053A (en)
OA (1)	OA10687A (en)
PE (1)	PE22898A1 (en)
PL (1)	PL326981A1 (en)
SK (1)	SK63098A3 (en)
TN (1)	TNSN96141A1 (en)
TR (1)	TR199800902T2 (en)
WO (1)	WO1997018814A1 (en)
YU (1)	YU62096A (en)
ZA (1)	ZA969722B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5945125A (en) *	1995-02-28	1999-08-31	Temple University	Controlled release tablet
CA2314993A1 (en) *	1997-12-16	1999-06-24	Pfizer Products Inc.	Combination effective for the treatment of impotence
AP1224A (en)	1998-03-19	2003-11-14	Bristol Myers Squibb Co	Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
GT199900061A (en) *	1998-05-15	2000-10-14	Pfizer	PHARMACEUTICAL FORMULATIONS.
EP0974343B1 (en) *	1998-07-22	2004-09-29	Pharma Pass II LLC	Process for manufacturing a solid metoprolol composition
EP0987020A1 (en) *	1998-09-04	2000-03-22	Pharma Pass LLC	Metoprolol composition and processes for manufacturing the same
CO5140079A1 (en) *	1998-10-14	2002-03-22	Novartis Ag	PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT
UA67802C2 (en)	1998-10-23	2004-07-15	Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А.	CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
US20030059467A1 (en) *	2001-09-14	2003-03-27	Pawan Seth	Pharmaceutical composition comprising doxasozin
TWI312285B (en)	2001-10-25	2009-07-21	Depomed Inc	Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) *	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
US7612112B2 (en)	2001-10-25	2009-11-03	Depomed, Inc.	Methods of treatment using a gastric retained gabapentin dosage
US8329217B2 (en)	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1680078A2 (en) *	2003-10-17	2006-07-19	Ranbaxy Laboratories, Ltd.	Oral matrix formulations of doxazosin
US20050255157A1 (en) *	2004-05-11	2005-11-17	Glenmark Pharmaceuticals Limited	Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (en) *	2004-05-28	2006-04-27	한미약품 주식회사	Sustained release composition for oral administration of niacin
DE102004054054A1 (en)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
KR100679111B1 (en) *	2004-11-20	2007-02-07	대우약품공업주식회사	Sustained-release tablets containing doxazosin
EP1919460A2 (en) *	2005-08-22	2008-05-14	Novartis AG	Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
US20090176882A1 (en)	2008-12-09	2009-07-09	Depomed, Inc.	Gastric retentive gabapentin dosage forms and methods for using same
ES2360423T3 (en)	2006-04-26	2011-06-03	Supernus Pharmaceuticals, Inc.	OXCARBAZEPIN CONTROLLED RELEASE PREPARATIONS THAT HAVE SIGMOIDAL RELEASE PROFILE.
EP2540725A1 (en)	2006-05-04	2013-01-02	Boehringer Ingelheim International GmbH	Polymorphs of 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20080251A1 (en)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	USES OF DPP IV INHIBITORS
CN100396282C (en) *	2006-07-25	2008-06-25	山东省医药工业研究所	Slow released doxazosin mesilate capsule and its prepn process
SA07280459B1 (en)	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
WO2009114648A1 (en)	2008-03-11	2009-09-17	Depomed Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en)	2008-03-11	2013-02-12	Depomed, Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PE20091730A1 (en)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	FORMULATIONS INVOLVING A DPP4 INHIBITOR
BRPI0916997A2 (en)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	DPP-4 INHIBITOR AND ITS USE
TWI478712B (en)	2008-09-30	2015-04-01	Astellas Pharma Inc	Pharmaceutical composition for modified release
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (en)	2008-12-17	2010-12-24	동아제약주식회사	Controlled Release Compositions for Preparing Udenafil-Containing Sustained-Release Formulations
JP5685550B2 (en)	2009-02-13	2015-03-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Pharmaceutical composition comprising SGLT2 inhibitor, DPP-IV inhibitor, and optionally antidiabetic agent, and use thereof
US9901551B2 (en)	2009-04-20	2018-02-27	Ambra Bioscience Llc	Chemosensory receptor ligand-based therapies
US8828953B2 (en)	2009-04-20	2014-09-09	NaZura BioHealth, Inc.	Chemosensory receptor ligand-based therapies
CN102481276A (en)	2009-04-20	2012-05-30	埃尔舍利克斯治疗公司	Chemosensory receptor ligand-based therapies
KR20240090632A (en)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US9198861B2 (en)	2009-12-22	2015-12-01	Mallinckrodt Llc	Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) *	2009-12-22	2011-06-23	Mallinkckrodt Inc.	Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
CN102946875A (en)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	Combination therapy
MY161846A (en)	2010-07-09	2017-05-15	James Trinca Green	Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
MX2013004364A (en)	2010-10-19	2013-07-02	Elcelyx Therapeutics Inc	Chemosensory receptor ligand-based therapies.
AR083878A1 (en)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
EP2661266B1 (en)	2011-01-07	2020-09-16	Anji Pharma (US) LLC	Chemosensory receptor ligand-based therapies
CN102058555A (en) *	2011-01-13	2011-05-18	北京汇诚瑞祥医药技术有限公司	Doxazosin controlled release tablet
AR085689A1 (en)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
CN102188431A (en) *	2011-05-09	2011-09-21	浙江九旭药业有限公司	Doxazosin mesylate sustained-release tablets and preparation method thereof
US9050335B1 (en)	2011-05-17	2015-06-09	Mallinckrodt Llc	Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en)	2011-05-17	2014-06-03	Mallinckrodt Llc	Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en)	2011-05-17	2014-10-14	Mallinckrodt Llc	Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US20130143867A1 (en)	2011-12-02	2013-06-06	Sychroneuron Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013158928A2 (en)	2012-04-18	2013-10-24	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
JP6224084B2 (en)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Xanthine derivatives as DPP-4 inhibitors for the treatment of glomerular epithelial cell related disorders and / or nephrotic syndrome
JP6218811B2 (en)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Xanthine derivatives as DPP-4 inhibitors for use in the treatment of SIRS and / or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014197744A1 (en)	2013-06-05	2014-12-11	Synchroneuron, Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3110449B1 (en)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medical use of a dpp-4 inhibitor
CN105616378A (en) *	2014-10-31	2016-06-01	康普药业股份有限公司	Fluconazole capsule and preparation method therefor
CN109310697A (en)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	Combination of linagliptin and metformin
US12097189B1 (en)	2024-02-09	2024-09-24	Astellas Pharma Inc.	Pharmaceutical composition for modified release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1198386B (en) *	1982-07-06	1988-12-21	Lepetit Spa	A PROTRACTED RELEASE PRODUCT CONTAINING SULOCTIDYL
US4765989A (en) *	1983-05-11	1988-08-23	Alza Corporation	Osmotic device for administering certain drugs
US4837111A (en) *	1988-03-21	1989-06-06	Alza Corporation	Dosage form for dispensing drug for human therapy
IL92966A (en) *	1989-01-12	1995-07-31	Pfizer	Dispensing devices powered by hydrogel
MX9100277A (en) *	1990-07-23	1992-02-28	Alza Corp	ORAL OSMOTIC DEVICE FOR APPLYING NICOTINE

1995
- 1995-11-21 GB GBGB9523752.5A patent/GB9523752D0/en active Pending
1996
- 1996-11-11 TR TR1998/00902T patent/TR199800902T2/en unknown
- 1996-11-11 KR KR1019980703777A patent/KR19990071505A/en not_active Ceased
- 1996-11-11 CN CN96198486A patent/CN1215993A/en active Pending
- 1996-11-11 SK SK630-98A patent/SK63098A3/en unknown
- 1996-11-11 JP JP9519364A patent/JPH10513481A/en active Pending
- 1996-11-11 NZ NZ322053A patent/NZ322053A/en unknown
- 1996-11-11 AU AU75721/96A patent/AU709560B2/en not_active Ceased
- 1996-11-11 WO PCT/EP1996/005020 patent/WO1997018814A1/en not_active Ceased
- 1996-11-11 HU HU9903734A patent/HUP9903734A3/en unknown
- 1996-11-11 CZ CZ981554A patent/CZ155498A3/en unknown
- 1996-11-11 BR BR9611626A patent/BR9611626A/en not_active Application Discontinuation
- 1996-11-11 CA CA002232715A patent/CA2232715A1/en not_active Abandoned
- 1996-11-11 PL PL96326981A patent/PL326981A1/en unknown
- 1996-11-11 EP EP96938215A patent/EP0862437A1/en not_active Withdrawn
- 1996-11-20 AR ARP960105252A patent/AR004335A1/en unknown
- 1996-11-20 PE PE1996000831A patent/PE22898A1/en not_active Application Discontinuation
- 1996-11-20 YU YU62096A patent/YU62096A/en unknown
- 1996-11-20 TN TNTNSN96141A patent/TNSN96141A1/en unknown
- 1996-11-20 ZA ZA9609722A patent/ZA969722B/en unknown
- 1996-11-20 MA MA24397A patent/MA26410A1/en unknown
- 1996-11-21 HR HR9523752.5A patent/HRP960554A2/en not_active Application Discontinuation
- 1996-11-21 AP APAP/P/1996/000883A patent/AP718A/en active
- 1996-11-21 CO CO96061449A patent/CO4480020A1/en unknown
1998
- 1998-03-31 IS IS4706A patent/IS4706A/en unknown
- 1998-05-08 BG BG102438A patent/BG102438A/en unknown
- 1998-05-19 OA OA9800058A patent/OA10687A/en unknown
- 1998-05-20 NO NO982302A patent/NO982302L/en not_active Application Discontinuation
- 1998-05-20 MX MX9804008A patent/MX9804008A/en unknown

Also Published As

Publication number	Publication date
OA10687A (en)	2002-11-27
BG102438A (en)	1999-01-29
KR19990071505A (en)	1999-09-27
HUP9903734A3 (en)	2000-04-28
TNSN96141A1 (en)	2005-03-15
HUP9903734A2 (en)	2000-03-28
CA2232715A1 (en)	1997-05-29
NZ322053A (en)	1999-11-29
CO4480020A1 (en)	1997-07-09
SK63098A3 (en)	1999-05-07
MX9804008A (en)	1998-09-30
GB9523752D0 (en)	1996-01-24
NO982302D0 (en)	1998-05-20
WO1997018814A1 (en)	1997-05-29
JPH10513481A (en)	1998-12-22
AP9600883A0 (en)	1997-01-31
ZA969722B (en)	1998-05-20
CZ155498A3 (en)	1999-03-17
TR199800902T2 (en)	1998-09-21
AU7572196A (en)	1997-06-11
PL326981A1 (en)	1998-11-09
CN1215993A (en)	1999-05-05
YU62096A (en)	1999-03-04
AU709560B2 (en)	1999-09-02
EP0862437A1 (en)	1998-09-09
AP718A (en)	1999-01-06
AR004335A1 (en)	1998-11-04
HRP960554A2 (en)	1998-02-28
BR9611626A (en)	1999-06-01
PE22898A1 (en)	1998-05-07
MA26410A1 (en)	2004-12-20
NO982302L (en)	1998-07-17

Publication	Publication Date	Title
IS4706A (en)	1998-03-31	pharmaceutical compositions
NO20004345L (en)	1996-12-23	Pharmaceutical composition
CY2005007I1 (en)	2009-11-04	PHARMACEUTICAL COMPOSITIONS CONTAINING DARIFENACINE
FI20071025L (en)	2007-12-28	Pharmaceutical compositions
FI974241L (en)	1997-12-02	BPM-15 compositions
ID18352A (en)	1998-04-02	PHARMACEUTICAL COMPOSITIONS
DE69617029D1 (en)	2001-12-20	ORGANOTON COMPOSITIONS
NO981568D0 (en)	1998-04-06	Randtennings-priming compositions
DE69614407D1 (en)	2001-09-13	PHARMACEUTICAL COMPOSITIONS
BR9507768A (en)	1997-09-02	Pharmaceutical composition
LV11727A (en)	1997-04-20	Pharmaceutical composition
FI973229A0 (en)	1997-08-05	New pharmaceutical composition
FI943705L (en)	1995-02-14	Pharmaceutical compositions
IS2515B (en)	2009-06-15	pharmaceutical compositions
PT941100E (en)	2003-10-31	PHARMACEUTICAL COMPOSITIONS
DE69603228D1 (en)	1999-08-19	Aluminoxanate compositions
EE200000330A (en)	2001-08-15	Pharmaceutical compositions
FI973280A7 (en)	1997-08-08	Pharmaceutical composition
ITMI942166A0 (en)	1994-10-21	PHARMACEUTICAL COMPOSITIONS MIORELAXANTS
FI940726A7 (en)	1994-08-19	Pharmaceutical compositions
ATE206150T1 (en)	2001-10-15	DYE-STABILIZED COMPOSITIONS
BR9605777A (en)	1998-08-25	Pharmaceutical composition
FI962738A7 (en)	1996-07-03	Pharmaceutical compositions
FI954050L (en)	1996-03-02	Pharmaceutical compositions
BR9605131A (en)	1998-07-07	Pharmaceutical composition